Lindsey BSc - Zymeworks Common Vice Development

ZYME Stock  USD 13.10  0.04  0.31%   

Executive

Lindsey BSc is Vice Development of Zymeworks Common Stock
Address 108 Patriot Drive, Middletown, DE, United States, 19709
Phone302 274 8744
Webhttps://www.zymeworks.com

Zymeworks Common Management Efficiency

The company has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 11, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.
Zymeworks Common Stock currently holds 26.72 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Zymeworks Common Stock has a current ratio of 3.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Zymeworks Common's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

JD EsqBluebird bio
52
Steven ClosterSyndax Pharmaceuticals
N/A
Steven CookCytokinetics
65
Scott HarrisTerns Pharmaceuticals
N/A
Debra DursoBumpusBlueprint Medicines Corp
54
Mahesh PadvalRelay Therapeutics
N/A
Shikhar MBAAnnexon
N/A
Deborah PalestrantRelay Therapeutics
N/A
Casey LoganTravere Therapeutics
N/A
Melita JungTerns Pharmaceuticals
47
CPA CPAArrowhead Pharmaceuticals
58
Christina RossiBlueprint Medicines Corp
47
Thomas LeggettStoke Therapeutics
47
Karen LewisApellis Pharmaceuticals
51
Pamela DanagherTerns Pharmaceuticals
N/A
Courtney DuganY mAbs Therapeutics
N/A
Aaron TanArrowhead Pharmaceuticals
N/A
Virginia MBAAlector
N/A
Jason HoittStoke Therapeutics
46
Chuck MillerMersana Therapeutics
N/A
Ariel HurleyBlueprint Medicines Corp
50
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 284 people. Zymeworks Common Stock (ZYME) is traded on NASDAQ Exchange in USA. It is located in 108 Patriot Drive, Middletown, DE, United States, 19709 and employs 294 people. Zymeworks Common is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Zymeworks Common Stock Leadership Team

Elected by the shareholders, the Zymeworks Common's board of directors comprises two types of representatives: Zymeworks Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zymeworks. The board's role is to monitor Zymeworks Common's management team and ensure that shareholders' interests are well served. Zymeworks Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zymeworks Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jack Spinks, Associate Relations
Neil MD, Chief Officer
Mark Hollywood, Executive Operations
Neil Josephson, Interim Chief Medical Officer
Anthony Polverino, Executive Vice President - Early Development, Chief Scientific Officer
Christopher Astle, Chief Financial Officer, Senior Vice President
Thomas Kreudenstein, Director Engineering
Paul Moore, Chief Officer
Diana Papove, Senior Communications
Jeffrey MD, Executive Officer
Diana Hausman, Chief Medical Officer
Nina Weisser, Director Therapeutics
Kenneth Galbraith, Chairman of the Board, President, Chief Executive Officer
Leone MBA, EVP CFO
Ryan Dercho, Senior Affairs
Lota Zoth, Lead Independent Director
Kenneth CA, CEO Chairman
Daniel JD, Corporate VP
Lindsey BSc, Vice Development
Shrinal Inamdar, Director Relations
Ali Tehrani, President, Chief Executive Officer, Co-Founder, Director
Neil Klompas, Chief Financial Officer, Executive Vice President - Business Operations
Josemund MBBS, Managing Pacific
Laura OConnor, Head Resources
John Fann, Senior Sciences
David Poon, VP Management

Zymeworks Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zymeworks Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.49)
Revenue Per Share
0.831
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.15)
Return On Equity
(0.29)
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.